London, Jul 1 (AP) Some British experts have slammed the US decision to snap up nearly the entire global supply of remdesivir, the only drug licensed so far to treat COVID-19.

Ohid Yaqub, a senior lecturer at the University of Sussex called it “disappointing news” in a statement.

Also Read | Nepal PM KP Sharma Oli, Who Was Taken to Sahid Gangalal National Heart Center in Kathmandu, Returns After Check Up.

“It so clearly signals an unwillingness to cooperate with other countries and the chilling effect this has on international agreements about intellectual property rights,” Yaqub said.

The U.S. government announced Tuesday that President Donald Trump had struck “an amazing deal” to buy the remdesivir drug for Americans, made by Gilead.

Also Read | India-China Talks: Expeditious, Stepwise De-Escalation Along LAC Emphasised in 3rd Commander Level Meeting, Says Report.

The Department of Health and Human Services said Trump has secured 500,000 treatments of the drug through September, representing 100 per cent of Gilead's July production capacity and 90 per cent of its capacity in August and September.

In earlier stages of the pandemic, the U.S. refused to export pre-ordered masks to other countries, including Canada.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)